Evaluation of the efficacy of Trazodone in improving emotional blunting symptoms in Patients with Major Depressive Disorder

Lab values

• Participant who meets any of the contraindications to the administration of the study medication according to the approved local SmPC. 2. Participant with inadequate response to two previous antidepressant treatment courses of adequate dosage and duration. 3. Known hypersensitivity or allergy to the active ingredient and/or to any component of the study medication. 4. Participant with current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders or mental disorders due to a general medical condition. 5. Participant with current history of a clinically significant neurological disorder, or any neurodegenerative disease, or other relevant condition that, in the opinion of the Investigator, might compromise participation in the study. 6. Participant that are under antipsychotics and/or mood stabilizers therapy. 7. Participant at risk of suicide, defined by a score ≥4 in MADRS item #10 at Baseline Visit. 8. Women during pregnancy or lactation period. 9. Clinically significant abnormalities on physical examination and vital signs (as assessed per routine clinical practice) at Baseline Visit which, in the opinion of the Investigator, could interfere with the study procedures or endpoints evaluation. 10. Participant with known cardiovascular disease including those associated with prolongation of the QT interval (e.g. QT Interval Corrected Using Fridericia's Formula (QTcF) value higher than 450 msec for male and QTcF value higher than 470 msec for female). 11. Inability to comply with the protocol requirements (i.e. uncooperative attitude, inability to return to study visits, unlikelihood of completing the clinical study). 12. Participant involved in the conduct of the study (e.g. Investigator or her deputy, first grade relatives, pharmacist, assistant or other personnel). 13. Participation in a interventional clinical trial within 3 months of Baseline Visit.

• Male and female outpatients of any ethnic origin aged 18-65 years (limits included) at Baseline visit. 2. Participant has a primary diagnosis of single or recurrent MDD according to DSM-5®. 3. Participant has had the current Major Depressive Episode (MDE) for <12 months. 4. Participant has a MADRS total score ≥ 22 and ≤ 28 at Baseline visit. 5. Participant has been treated with SSRI/SNRI monotherapy (e.g. citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, etc.) for at least 6 weeks at an adequate dose for the current MDE and with an inadequate response and is a candidate for a switch in the Investigator's opinion. 6. Participant has an ODQ total score ≥50 at enrolment visit, while on SSRI/SNRI monotherapy (prior to switch). 7. Written informed consent (including consent for the processing of personal data) signed by participant prior to entering the study following local regulation. 8. Women of childbearing potential must have a negative pregnancy test at Baseline Visit and have to agree not to start a pregnancy from the signature of the informed consent up to the Visit 3, using an appropriate birth control method such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence.